Return to site
Return to site

Bet hongkong ag

broken image

“With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.

broken image

PLANEGG/MUNICH, Germany-( BUSINESS WIRE)-MorphoSys AG (FSE: MOR NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.

broken image

 

PreviousNext
Cookie Use
We use cookies to improve browsing experience, security, and data collection. By accepting, you agree to the use of cookies for advertising and analytics. You can change your cookie settings at any time. Learn More
Accept all
Settings
Decline All
Cookie Settings
Necessary Cookies
These cookies enable core functionality such as security, network management, and accessibility. These cookies can’t be switched off.
Analytics Cookies
These cookies help us better understand how visitors interact with our website and help us discover errors.
Preferences Cookies
These cookies allow the website to remember choices you've made to provide enhanced functionality and personalization.
Save